Loading
A phase 1/2 trial of Cobolimab, Dostarlimab in melanoma and hodgkin lymphoma, run by GlaxoSmithKline, active and no longer recruiting.
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer is a phase 1/2 interventional study registered as NCT06521567 by GlaxoSmithKline, with 83 participants planned, started 2025-03-06 and due to reach its primary completion in 2026-10-13. Interventions recorded: Cobolimab, Dostarlimab. Conditions listed: Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TIM-3 blockade, Cobolimab, GSK.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares TIM-3 blockade, Cobolimab.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/